دورية أكاديمية

Immune profile and mitotic index of metastatic melanoma lesions enhance clinical staging in predicting patient survival.

التفاصيل البيبلوغرافية
العنوان: Immune profile and mitotic index of metastatic melanoma lesions enhance clinical staging in predicting patient survival.
المؤلفون: Bogunovic, Dusan, O'Neill, David W., BeIitskaya-Levy, Ilana, Vacic, Vladimir, Yi-Lo Yu, Adams, Sylvia, Darvishian, Farbod, Berman, Russell, Shapiro, Richard, Pavlick, Anna C., Lonardi, Stefano, Zavadil, Jiri, Osman, Iman, Bhardwaj, Nina
المصدر: Proceedings of the National Academy of Sciences of the United States of America; 12/1/2009, Vol. 106 Issue 48, p20429-20434, 6p
مصطلحات موضوعية: MELANOMA, DISEASE progression, METASTASIS, GENE expression, LEUCOCYTES, IMMUNE response, CELL proliferation
مستخلص: Although remission rates for metastatic melanoma are generally very poor, some patients can survive for prolonged periods following metastasis. We used gene expression profiling, mitotic index (MI), and quantification of tumor infiltrating leukocytes (TILs) and CD3+ cells in metastatic lesions to search for a molecular basis for this observation and to develop improved methods for predicting patient survival. We identified a group of 266 genes associated with postrecurrence survival. Genes positively associated with survival were predominantly immune response related (e.g., ICOS, CD3d, ZAP70, TRAT1, TARP, GZMK, LCK, CD2, CXCL13, CCL19, CCR7, VCAM1) while genes negatively associated with survival were cell proliferation related (e.g., PDE4D, CDK2, GREF1, NUSAP1, 5PC24). Furthermore, any of the 4 parameters (prevalidated gene expression signature, TILs, CD3, and in particular Ml) improved the ability of Tumor, Node, Metastasis'(TNM) staging to predict postrecurrence survival; Ml was the most significant contributor (HR = 2.13, P = 0.0008). An immune response gene expression signature and presence âf TIL5 and CD3+ cells signify immune surveillance as a mechanism for prolonged survival in these patients and indicate improved patient subcategorization beyond current TNM staging. [ABSTRACT FROM AUTHOR]
Copyright of Proceedings of the National Academy of Sciences of the United States of America is the property of National Academy of Sciences and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
قاعدة البيانات: Complementary Index
الوصف
تدمد:00278424
DOI:10.1073/pnas.0905139106